Cabaletta Bio, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CABA Nasdaq 2834 www.cabalettabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cabaletta Bio, Inc.

Kyverna Therapeutics Sinks 13%: Here’s Why - Jul 10th, 2026 1:59 pm
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup - Jun 17th, 2026 9:16 am
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Jun 9th, 2026 7:00 am
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Jun 7th, 2026 11:58 am
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - Jun 3rd, 2026 5:00 am
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis - May 21st, 2026 5:42 am
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - May 20th, 2026 7:40 am
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - May 18th, 2026 10:00 am
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - May 14th, 2026 5:05 am
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - May 14th, 2026 5:00 am
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering - May 4th, 2026 4:35 am
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - Apr 28th, 2026 6:00 am
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting - Apr 27th, 2026 3:00 pm
This Biotech Stock Could Deliver 350% Returns in 12 Months - Mar 27th, 2026 11:11 am
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Mar 23rd, 2026 5:30 am
Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference - Mar 7th, 2026 3:46 am
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know - Mar 6th, 2026 10:00 am
Are Medical Stocks Lagging Biodesix (BDSX) This Year? - Mar 3rd, 2026 7:40 am
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference - Feb 24th, 2026 6:00 am
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA) - Feb 18th, 2026 6:34 am